Randomized,double-blind,placebo-controlled,safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Randomized,double-blind,placebo-controlled,safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers

Authors:	Robert J Hopkins Nancy F Daczkowski Paulina E Kaptur Derek Muse Eric Sheldon Craig LaForce Suha Sari Thomas L Rudge Edward Bernton

Institution:	1. Emergent BioSolutions Inc., Gaithersburg, MD, USA;2. Jean Brown Research, Salt Lake City, UT, USA;3. Miami Research Associates, South Miami, FL, USA;4. North Carolina Clinical Research, Raleigh, NC, USA;5. Battelle Memorial Institute, Columbus, OH, USA

Abstract:	A new anthrax vaccine that could accelerate the immune response and possibly reduce the number of injections needed for protection would be desirable in a post-exposure setting.

Keywords:	ACIP Advisory Committee on Immunization Practices AE adverse event ALC absolute lymphocyte count ANOVA analysis of variance AVA Anthrax Vaccine Adsorbed AV7909 AVA plus CPG 7909 CI confidence interval CPG cytosine-phosphate-guanine oligonucleotide CRP C-reactive protein EBS Emergent BioSolutions Inc ELISA enzyme-linked Immunosorbent assay GI gastrointestinal GMT geometric mean titer HLA human leukocyte antigen IFN interferon IL interleukin IM intramuscular IP interferon-inducible protein NF₅₀ 50% neutralization factor ODN oligodeoxynucleotide PA protective antigen PBMC peripheral blood mononuclear cells PEP post-exposure prophylaxis rPA recombinant protective antigen SAE serious adverse event SC subcutaneous SD standard deviation SEM standard error of the mean Th1 type of T helper cell TNA toxin neutralizing antibody TRL toll-like receptor
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏